BURBANK, Calif., May 3, 2006 (PRIMEZONE) -- Imaging3(tm), Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, today provided an overview of its upcoming new product, The Dominion(tm) and its anticipated role in the rapid evolution of treatment techniques sweeping over the neurovascular market.
The neurovascular market treats problems related to nerve cells and the blood vessels that surround them. These disorders include strokes and aneurysms, as well as nerve related injuries such as carpal tunnel, tri-geminal neuralgia and others.
Helping to accelerate a revolution in treatment techniques
Today, over 70% of the 163,000 annual subarachnoid hemorrhages, unruptured aneurysms and other intracranial bleeding disorders (hemorrhagic stroke) are treated via open neurosurgical techniques. Endovascular embolization products and techniques -- microscopic treatments and procedures that are performed from inside the blood vessels -- that can be used by neurosurgeons and interventional neuroradiologists will eventually make up the majority of these procedures, as they have been documented to improve outcomes and reduce complications. An array of endovascular products is needed to stop or redirect blood flow in these pathologies and this medical device market is predicted to grow to nearly $600 million per year worldwide by 2010.
"This shift towards Endovascular procedures will require extremely accurate and reliable imaging as provided by our Dominion product. Real time 3D visualization will enable physicians to perform these procedures with more confidence while decreasing recovery time for patients. Endovascular surgery in the brain requires a high level of skill and requires state of the art imaging, which is why we expect that the Dominion will be highly sought after," stated Dean Janes.
The Dominion(tm) with its breakthrough real time 3D imaging will enable surgeons to have greater accuracy and increase their performance and speed while performing these procedures. By being able to view the human body in 3D in real time the physician will more accurately diagnose and treat patients with Neuro vascular disorders. The ability to guide catheters, placing balloon catheters and stents will be greatly increased with 3D real time visualization without having to reposition equipment or reorient the patient. The Dominion(tm) and its ability to display images in 3D real time will extremely valuable to diagnose and perform procedures in this extremely sensitive area, the human brain. Many products exist to facilitate guidance in and around the brain, but nothing exists in 3D real time and many are combinations of several devices.
About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company's website at www.imaging3.com
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.